incredible-marketing Arrow
Androgenic Alopecia Patient

Androgenic Alopecia

Androgenic alopecia aka “genetic hair loss,” predominantly affects men between the late teenage years and late 40s, and women around age 50 or later; however, can occur in both genders at any time post-puberty. Over time, the conversion of healthy terminal hair follicles into nonpigmented vellus follicles will take place. Eventually, if the cause of the destruction is not identified, and treated diffuse alopecia areata (shiny bald section) will be permanent. Onset is usually gradual and progresses with triggers.


Patients often have a familial history of baldness, and the severity is highly correlated. Other causes can progress the rate of loss, and a complete history and physical exam along with bloodwork should be conducted if secondary causes are speculated. A biopsy may be indicated if an identifiable cause is not found. For example, the following labs should be drawn if suspected:

  • Dehydroepiandrosterone (DHEA)-sulfate and testosterone analysis: In women, if virilization is evident
  • Iron, total iron-binding capacity, and transferrin saturation: To test for iron deficiency, if telogen effluvium is present
  • Thyrotropin level: If a thyroid disorder is suspected
Androgenic Alopecia


Treatment varies based on the other conditions that could accelerate the condition. Sophia Michelle Aesthetics will conduct a thorough evaluation, and develop a treatment plan that optimizes your hairs health. Some of the below treatments can include:

  • Hair & Scalp Therapy
  • Nutritional modification,
  • Medications:
    • Androgen Receptor Antagonists:
      • Spironolactone
      • Minoxidil: Androgen-independent hair-growth stimulator
      • Finasteride: 5-Alpha-reductase type 2 inhibitor
  • Low-Level Laser Therapy
    • Thermadome
  • Platelet Rich Plasma (PRP) with Placenta-Derived Extracellular Matrix Therapy
  • Microneedling
  • Scalp Micropigmentation
  • Camouflaging Hair Products
  • Future potential therapy: Bioengineered, nonrecombinant, human cell-derived formulation containing follistatin, keratinocyte growth factor (KGF), and vascular endothelial growth factor (VEGF)